BioSpace News Archive

Brii Biosciences Limited presented new data from two Phase 2 studies evaluating BRII-179 either as a combination therapy with BRII-835 (elebsiran) or as an add-on therapy to pegylated interferon-alpha (PEG-IFNα) treatment for chronic hepatitis B virus (HBV) infection at the EASL™ (European Association for the Study of the Liver) Congress 2024.

In a breakthrough randomized, controlled, clinical trial just released publicly on June 7, 2024 , researchers demonstrated that, after 20 weeks, an intensive lifestyle intervention, without drugs, significantly improved cognition and function in many patients with early-stage Alzheimer’s disease.

Kura Oncology, Inc. today announced that on June 3, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 152,500 shares of common stock to eight (8) new employees.

Nusano, Inc., a physics company transforming the production of medical radioisotopes, announced industry veteran D. Scott Holbrook as chairman of its board.

Replimune Group, Inc. announced that Sushil Patel, Chief Executive Officer of Replimune, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 2:00 PM ET.

Johnson & Johnson MedTech* announced that DePuy Synthes, The Orthopaedics Company of Johnson & Johnson**, has received 510 FDA clearance for the clinical application of the VELYS™ Robotic-Assisted Solution in Unicompartmental Knee Arthroplasty.

Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, announced its participation in the upcoming FSHD International Research Congress being held June 13-14, 2024, in Denver, Colo.

BioMarin Pharmaceutical Inc. will be presented at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Bangkok, Thailand, June 22-26, 2024.

ImmunityBio, Inc. ( NASDAQ: IBRX ) announced today that its 2024 Annual Meeting of Stockholders will be held on Tuesday, June 11, 2024 at 9:30 a.m. Pacific Time.

Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference.